Glaucoma Clinical Trial
Official title:
A Single Centre, Placebo-Controlled, Double-Masked, Sequential Designed Study to Evaluate 3 Ophthalmic Formulations of AMA0076 in Healthy Subjects
Verified date | May 2014 |
Source | Amakem, NV |
Contact | n/a |
Is FDA regulated | No |
Health authority | United Kingdom: Medicines and Healthcare Products Agency |
Study type | Interventional |
A Single Centre, Placebo-Controlled, Double-Masked, Sequential Designed Study to Evaluate 3 Ophthalmic Formulations of AMA0076 in Healthy Subjects
Status | Completed |
Enrollment | 21 |
Est. completion date | December 2013 |
Est. primary completion date | December 2013 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 35 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Healthy males and non-pregnant, non-lactating females, aged 35 to 65 years. - Body mass index of =35kg/m2. - IOP between 15 and 24 mmHg (inclusive) in both eyes at Screening Visits 1 and 2. Exclusion Criteria: - Women of child-bearing potential who have a positive pregnancy test. - Any subject deemed by the investigator to have uncontrolled systemic hypertension - Use of systemic, inhaled or ocular corticosteroid treatment within 90 days of screening or likely to require their use during the study period. - Any screening laboratory abnormality that, in either the investigator's or the medical monitor's judgment, is considered to be clinically significant or a safety risk. - History of any clinically significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or influence the results of the subject's ability to participate in the study, or interfere with interpretation of the subject's study results. - Participation in any other clinical study within 1 month of screening or during the study. - Receipt of another investigational drug within 90 days of dosing in this study - Diagnosis of any form of glaucoma. - IOP >24 mmHg in either eye at any screening visit. - Use of any ocular drops (including lubricating drops/artificial tears) during screening period or need for ocular drops during duration of study participation. - In the opinion of the investigator, clinically significant eye trauma within 6 months of screening. - Any intraocular ophthalmic procedure within 6 months of screening. - Any ocular inflammation within 90 days of screening or a history of recurrent uveitis in either eye. - Subjects with any known ocular disease and who are under care of a hospital ophthalmologist. - Any condition preventing valid applanation tonometry measurement. - Unable to discontinue contact lens wear during the study - Visual acuity (VA) worse than 20/80 in either eye - Subjects who are study site employees, or immediate family members of a study site or sponsor employee. - History of any drug or alcohol abuse in the past 2 years. - Regular alcohol consumption. - Positive drugs of abuse test result. - Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results - Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients - Presence or history of clinically significant allergy requiring treatment, as judged by the investigator. Hayfever is allowed unless it is active. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Amakem, NV |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Intraocular Pressure | The primary endpoint is the comparison of Intraocular Pressure assessments taken at pre-treatment on Day -1 and on Day 7 for each diurnal time point (0, 2, 4 and 8 h post-anticipated dose [Day -1] or post-dose [Day 7]) for each treatment period between active treatment and placebo. | 7 days | No |
Secondary | Safety and Tolerability | The secondary endpoints are: Comparison of hyperaemia assessments in each eye using a photographic rating scale on Day -1 (0 and 8 h post-anticipated dose) and Day 7 (0, 2, 4 and 8 h post dose) Assessment of ocular surface photographic images of each eye on Day -1 and Day 7 (0 h). Safety laboratory assessments, vital signs, 12-lead electrocardiogram (ECG), recording of Adverse Events and ophthalmic examination findings including visual acuity. |
7 days | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06000865 -
Glaucoma Rehabilitation With Action viDeo Games and Exercise - GRADE
|
N/A | |
Recruiting |
NCT06278597 -
Automatic Evaluation of the Anterior Chamber Angle Width by a New Non-contact Optical Device
|
N/A | |
Active, not recruiting |
NCT04271709 -
Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)
|
N/A | |
Recruiting |
NCT03274024 -
The Asia Primary Tube Versus Trab (TVT) Study
|
N/A | |
Completed |
NCT04552964 -
Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma
|
N/A | |
Recruiting |
NCT01957267 -
Functional and Structural Imaging for Glaucoma
|
||
Active, not recruiting |
NCT04624698 -
iStent Inject New Enrollment Post-Approval Study
|
N/A | |
Completed |
NCT04020705 -
The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma
|
N/A | |
Completed |
NCT03150160 -
Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma
|
Phase 4 | |
Not yet recruiting |
NCT05581498 -
Glaucoma Exercise as Medicine Study (GEMS).
|
N/A | |
Recruiting |
NCT02921568 -
Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes
|
N/A | |
Active, not recruiting |
NCT02901730 -
Clinical Study of LPI With Different Laser Wavelengths
|
N/A | |
Completed |
NCT02955849 -
A Trial of China Laser and Surgery Study Glaucoma in Rural China
|
Early Phase 1 | |
Recruiting |
NCT02554214 -
Pilot Clinical Trial on a New Adjustable Glaucoma Drainage Device
|
N/A | |
Recruiting |
NCT02471105 -
Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml
|
Phase 4 | |
Active, not recruiting |
NCT02390284 -
Stop Retinal Ganglion Cell Dysfunction Study
|
Phase 3 | |
Completed |
NCT02653963 -
Triamcinolone for Ahmed Glaucoma Valve
|
N/A | |
Completed |
NCT02246764 -
Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
|
Phase 3 | |
Completed |
NCT02628223 -
180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma
|
N/A | |
Completed |
NCT02390245 -
Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study
|
N/A |